As reported in Jun 2017 (#msg-132328161), both phase-3 trials met the primary endpoint of showing non-inferiority to Eylea in BCVA (Best Corrected Visual Acuity), the standard efficacy metric for AMD.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.